Rob is a Partner at Endeavour Vision focused on medical technology investments. Rob represents Endeavour Vision on the board of Willow and he has been on the deal team for investments in IntelyCare, Nalu, Rapid Micro Biosystems and Relievant Medsystems.
Rob joined Endeavour Vision after 15 years at Boston Scientific, which has been one of the most active acquirers in medical technology in recent years. In his role as Vice President, Corporate Business Development, Rob was responsible for leading the identification, assessment and execution of Business Development transactions for Boston Scientific’s Interventional Cardiology, Peripheral Intervention and Rhythm Management divisions. This included acquisitions, divestitures, minority investments and joint ventures.
Prior to his Business Development role, Rob held leadership positions in commercial strategy and marketing at Boston Scientific. Rob also previously worked at The 3M Company where he was an Engineering Project Leader.
Rob holds a BS in Chemical Engineering from Northwestern University and an MBA and a Masters in Engineering Management from The Kellogg School of Management.